Business Wire

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer

Share

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in The Lancet Oncology.

Based on the results, Servier filed a new application for an additional indication for gastric cancer to the European Medicines Agency (EMA) for LONSURF®.

“Patients with metastatic gastric cancer currently have limited treatment options after first and second line therapies have failed,” said Dr. Arkenau. “We are pleased to present new data that demonstrate the overall survival clinical benefit of trifluridine/tipiracil in metastatic gastric and gastroesophageal cancer.”

In TAGS patients treated with trifluridine/tipiracil showed a clinically meaningful and statistically significant improvement in OS compared with placebo and a 31 percent risk reduction of death (HR 0.69 one sided p=0.00029), which translated into a prolonged median survival of 2.1 months (5.7 months for trifluridine/tipiracil versus 3.6 months for placebo). In addition, trifluridine/tipiracil demonstrated a statistically significant improvement in PFS and time to deterioration of ECOG performance status versus placebo, as well as a predictable and manageable safety profile consistent with that previously reported in patients with metastatic colorectal cancer.

“We’re very excited by the results of TAGS as they show trifluridine/tipiracil has the potential to make a difference to the lives of people living with metastatic gastric cancer who continue to struggle with this devastating disease,” said Patrick Therasse, Head of Servier Research and Development Oncology Department.

Trifluridine/tipiracil is currently indicated in 61 countries, including those of the European Union, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1

The abstract for the trifluridine/tipiracil presentation is available on the ESMO website and the manuscript is published online in The Lancet Oncology.

ENDS

About TAGS
TAGS ( TA S-102 G astric S tudy) is a Taiho-sponsored pivotal Phase III, multinational, randomized, double-blind study evaluating trifluridine/tipiracil, also known as TAS-102, plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer, including gastro esophageal junction cancer, refractory to standard treatments. The primary endpoint in the TAGS trial is overall survival (OS), and the main secondary endpoint measures include progression-free survival (PFS), and safety and tolerability, as well as quality of life.

TAGS enrolled 507 adult patients with metastatic gastric cancer who had previously received at least two prior regimens for advanced disease. The study was conducted in Japan, the United States, the European Union, Russia, Belarus, Israel, and Turkey.

For more information on TAGS, please visit www.ClinicalTrials.gov ( https://clinicaltrials.gov/ct2/show/NCT02500043). The ClinicalTrials.gov Identifier is NCT02500043.

About Metastatic Gastric Cancer
Gastric cancer, also known as stomach cancer, is a disease in which malignant cells form in the lining of the stomach. It is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimated 723,000 deaths annually.2 

When cancer spreads it is called advanced cancer. Locally advanced cancer is when the cancer has grown outside the organ it started in but hasn’t spread to other parts of the body. When the cancer spreads to other parts of the body this is called metastatic cancer. In the last two decades, the proportion of patients with gastric cancer who present with metastases has risen to over 40%.3

Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes (with ramucirumab), or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third-line treatments are limited.

About LONSURF ® (trifluridine and tipiracil, TAS-102)
LONSURF ® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF ® is registered in Japan, USA, European Union, and in many other countries. In the European Union, LONSURF ® is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1

LONSURF ® is recommended by the National Institute for Health and Care Excellence (NICE),4 NCCN5,6 and ESMO Guidelines7 for the treatment of adult patients with metastatic CRC.

In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of LONSURF ® .

As of October 2018, LONSURF ® has been approved as a treatment for mCRC in 61 countries and regions worldwide.

About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as various leukemias and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, and targeted therapies, to deliver life-changing medicines to patients.

For more information about Servier, please visit www.servier.com .

About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives.

For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/.

ENDS

1 EMA. Summary of product characteristics: LONSURF. Available at: https://www.ema.europa.eu/documents/product-information/lonsurf-epar-product-information_en.pdf Accessed October 2018.

2 Ferlay J, Soerjomataram I, Dikshit R, et al. Int J Cancer. 2015;136:E359-86.

3 Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–60.

4 NICE TA405. Available at: www.nice.org.uk/guidance/TA405 Accessed October 2018.

5 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

6 National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.

7 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.

Contact information

Servier
Sonia MARQUES
media@servier.com
Tél. +33-(0)1-55-72-40-21 / + 33-(0)-7-84-28-76-13
or
Karine BOUSSEAU
media@servier.com
Tél. +33-(0)1-55-72-60-37

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks6.6.2020 10:05:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses suggest that TAKHZYRO® (lanadelumab) is well-tolerated and can prevent hereditary angioedema (HAE) attacks over an extended treatment period, with sustained and consistent reduction in monthly attack rate across a range of different patient subgroups. The data are being presented at the 2020 European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress. The original Phase 3 HELP Study was conducted in 125 patients aged 12 years and older over 26 weeks, making it the largest randomised, controlled prevention study in HAE, with the longest active treatment duration, to date.1 The HELP Study OLE was designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO for up to 2.5 years and was completed in Novemb

Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!5.6.2020 12:10:00 EESTPress release

Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value. As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service. “Datalytyx said they could

Pegasus Development AG: Green Light for Multiple Production Sites Worldwide5.6.2020 10:27:00 EESTPress release

Announcement: Expansion of the Pegastril-Nuevo production facility Under the leadership of board member Roberto Spano, the management of Pegasus Development AG has decided to further expand Pegastril-Nuevo production facilities. New production facilities will be set up at several locations across the world and the site in Turkey is being expanded. These investments will also create new jobs. The takeover and expansion of the following production facilities are planned in all 20 countries of Latin America, as well as France, Spain, Portugal, Greece, Cyprus, Nigeria, Ethiopia, Uganda, Tanzania, Mozambique, Angola, Mauritius, Guinea-Bissau, Cape Verde, São Tome, and Mongolia. The demand for disinfectants has skyrocketed as a result of the coronavirus. Especially high revenues are expected from products which are based on vegetable surfactants and are alcohol-free, such as Nuevo. This was the decisive factor in the management's decision to further expand the quantity and range of Nuevo pro

IDEMIA and BBVA Partner to Launch Spain’s First Payment Card Made of Recycled PVC5.6.2020 10:00:00 EESTPress release

IDEMIA, the global leader in Augmented Identity, is supplying the very first cards made out of recycled plastics in Spain to BBVA. The bank will first distribute the cards to their Spanish customers with a BBVA Youth Account in June 2020. This new payment card is a strong commitment from BBVA to contributing to the United Nations Sustainable Development Goals for the fight against climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005037/en/ (Graphic: Business Wire) Each year, approximately 6 billion plastic payment cards are produced according to the 2018 Nilson Report1. In the context of the United Nations Sustainable Development Goals and the Paris Agreement, IDEMIA’s cutting-edge technology has been selected by BBVA, one of the largest banks in Spain, to migrate part of its existing first-use PVC cards to innovative recycled PVC cards. By the end of the year BBVA will enable more than half a million Spa

In COVID-19, Pudu Robotics Provides Non-contact Delivery Service in Hundreds of Hospitals Worldwide5.6.2020 10:00:00 EESTPress release

During COVID-19, hundreds of Pudu Robotics’ robot Pudubot is offering delivery service in hospitals worldwide. This non-contact delivery service by Pudubot helps avoid the spread of virus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005095/en/ (Photo: Business Wire) After the outbreak of COVID-19, the pandemic with the characteristic of human-to-human transmission, a large number of hospitals and restaurants are seeking help from Pudu Robotics out of an urgent need for non-contact delivery. Pudu Robotics responded positively by devoting robots to several hospitals in Seoul, South Korea, Beijing, China, Wuhan, China and so on. Because Pudu Robotics’ robots are fully automatic, they can achieve the delivery process all by themselves, which reduces contact between people and effectively prevents the spread of the virus. Pudubot is equipped with multi-sensor and positioning and navigation technology. With large-capacity

EIT Digital: Strengthening European Digital Infrastructure and Data Sovereignty5.6.2020 07:00:00 EESTPress release

Recent discussions around access to 5G technology and COVID-19 contact tracing apps highlight the need for European digital sovereignty. In its latest policy perspective report on ‘European Digital Infrastructure- and Data Sovereignty’, EIT Digital offers a concrete scenario-based framework for digital policy development. The study provides an overview of policy motivations, trends, instruments, and the roles of various actors in defining the perception of and perspectives for Europe’s digital sovereignty. “What becomes clear is that we need coordinated action between the policy shapers at European and national levels and the makers from business and industry to create a sovereign European digital reality. Key are policies that enhance innovation and respect European values and rights while creating equal economic opportunity for all actors,” says EIT Digital CEO Willem Jonker. EIT Digital collaborated with the Digital Enlightenment Forum to execute the report. The study supports the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom